Ascendis Pharma is a leading biopharma company focused on endocrinology rare diseases using their TransCon technology platform. The company has three approved medicines for hypoparathyroidism and growth disorders, with aspirations to drive >€5B annual revenue by 2030.
| Asset | Target | Stage | Lead Indication | Next Catalyst |
|---|---|---|---|---|
| Palopegteriparatide_YORVIPATH_TransCon_PTH | PTH receptor | Approved | — | |
| QW_TransCon_PTH | Parathyroid hormone | Preclinical | — | |
| SKYTROFA_TransCon_hGH | Human growth hormone | Approved | — | |
| TransCon_aVEGF_EYC-0305 | VEGF | Preclinical | — | |
| TransCon_CNP | C-type natriuretic peptide pathway | Phase 3 | — | |
| TransCon_CNP_navepegritide | C-type natriuretic peptide | NDA Submitted | — | |
| TransCon_FGF-23_degrader | Fibroblast growth factor 23 | Preclinical | — | |
| TransCon_hGH | Growth hormone pathway | Phase 2 | — | |
| TransCon_IL-2_b_g | Interleukin-2 | Phase 2 | TransCon IL-2 β/γ IL-Believe program update (PROC OS) (Q4 2026) | |
| TransCon_semaglutide | GLP-1 receptor | Preclinical | — | |
| YORVIPATH_TransCon_PTH | Parathyroid hormone | Approved | — |